TSE:VRX - Valeant Pharmaceuticals International Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
C$28.24 -0.30 (-1.05 %)
(As of 05/23/2018 06:50 AM ET)
Previous CloseC$28.54
Today's RangeC$28.09 - C$28.53
52-Week RangeC$14.01 - C$30.56
Volume807,200 shs
Average Volume1.47 million shs
Market CapitalizationC$7.69 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.76

About Valeant Pharmaceuticals International (TSE:VRX)

Valeant Pharmaceuticals International logoValeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.

Receive VRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
SymbolTSE:VRX
CUSIPN/A
Phone+1-514-7446792

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins58.58%
Return on Equity112.73%
Return on Assets12.76%

Miscellaneous

EmployeesN/A
Outstanding Shares348,840,000

Valeant Pharmaceuticals International (TSE:VRX) Frequently Asked Questions

What is Valeant Pharmaceuticals International's stock symbol?

Valeant Pharmaceuticals International trades on the Toronto Stock Exchange (TSX) under the ticker symbol "VRX."

How were Valeant Pharmaceuticals International's earnings last quarter?

Valeant Pharmaceuticals International Inc (TSE:VRX) announced its quarterly earnings results on Wednesday, February, 28th. The specialty pharmaceutical company reported $1.24 earnings per share for the quarter, hitting the consensus estimate of $1.24. The specialty pharmaceutical company had revenue of $2.75 billion for the quarter, compared to the consensus estimate of $2.73 billion. Valeant Pharmaceuticals International had a return on equity of 112.73% and a net margin of 58.58%. View Valeant Pharmaceuticals International's Earnings History.

When is Valeant Pharmaceuticals International's next earnings date?

Valeant Pharmaceuticals International is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Valeant Pharmaceuticals International.

What price target have analysts set for VRX?

3 analysts have issued 12 month target prices for Valeant Pharmaceuticals International's shares. Their predictions range from C$23.00 to C$25.50. On average, they expect Valeant Pharmaceuticals International's share price to reach C$24.25 in the next year. View Analyst Ratings for Valeant Pharmaceuticals International.

Who are some of Valeant Pharmaceuticals International's key competitors?

Who are Valeant Pharmaceuticals International's key executives?

Valeant Pharmaceuticals International's management team includes the folowing people:
  • Mr. Joseph C. Papa, CEO & Chairman (Age 63)
  • Mr. Paul S. Herendeen, Exec. VP & CFO (Age 62)
  • Ms. Christina M. Ackermann, Exec. VP & Gen. Counsel (Age 53)
  • Mr. J. Michael Pearson, Former Chief Exec. Officer (Age 59)
  • Mr. Osama A. Eldessouky, Sr. VP, Controller & Chief Accounting Officer (Age 46)

Has Valeant Pharmaceuticals International been receiving favorable news coverage?

Media coverage about VRX stock has been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Valeant Pharmaceuticals International earned a daily sentiment score of 0.11 on Accern's scale. They also gave news articles about the specialty pharmaceutical company an impact score of 45.92 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Valeant Pharmaceuticals International?

Shares of VRX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Valeant Pharmaceuticals International's stock price today?

One share of VRX stock can currently be purchased for approximately C$28.24.

How big of a company is Valeant Pharmaceuticals International?

Valeant Pharmaceuticals International has a market capitalization of C$7.69 billion.

How can I contact Valeant Pharmaceuticals International?

Valeant Pharmaceuticals International's mailing address is 2150 Saint-Elzear Blvd W, LAVAL, QC H7L 4A8, Canada. The specialty pharmaceutical company can be reached via phone at +1-514-7446792.


MarketBeat Community Rating for Valeant Pharmaceuticals International (VRX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  265 (Vote Underperform)
Total Votes:  485
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals International and other stocks. Vote "Outperform" if you believe VRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Valeant Pharmaceuticals International (TSE:VRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Valeant Pharmaceuticals International in the last 12 months. Their average twelve-month price target is C$24.25, suggesting that the stock has a possible downside of 14.13%. The high price target for VRX is C$25.50 and the low price target for VRX is C$23.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.672.502.502.40
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: C$24.25C$22.50C$22.50C$22.50
Price Target Upside: 14.13% downside18.86% upside18.86% upside18.86% upside

Valeant Pharmaceuticals International (TSE:VRX) Consensus Price Target History

Price Target History for Valeant Pharmaceuticals International (TSE:VRX)

Valeant Pharmaceuticals International (TSE:VRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/8/2017Royal Bank of CanadaReiterated RatingSector PerformC$23.00View Rating Details
11/8/2017TD SecuritiesUpgradeHold ➝ BuyC$25.50View Rating Details
6/29/2017Cantor FitzgeraldReiterated RatingOverweightView Rating Details
5/10/2017ScotiabankBoost Price TargetSector PerformC$19.00View Rating Details
12/15/2016Morgan StanleyDowngradeOverweight ➝ Equal WeightView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Valeant Pharmaceuticals International (TSE:VRX) Earnings History and Estimates Chart

Earnings by Quarter for Valeant Pharmaceuticals International (TSE:VRX)

Valeant Pharmaceuticals International (TSE:VRX) Earnings Estimates

2018 EPS Consensus Estimate: $3.12
2019 EPS Consensus Estimate: $4.58
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181$1.01$1.01$1.01
Q3 20182$0.90$1.20$1.05
Q4 20182$0.91$1.20$1.06
Q1 20191$1.08$1.08$1.08
Q2 20191$1.12$1.12$1.12
Q3 20191$1.17$1.17$1.17
Q4 20191$1.21$1.21$1.21

Valeant Pharmaceuticals International (TSE VRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2018        
2/28/2018Q4 2017C$1.24C$1.24C$2.73 billionC$2.75 billionViewN/AView Earnings Details
11/7/2017Q3 2017C$1.13C$1.30C$2.74 billionC$2.78 billionViewN/AView Earnings Details
8/8/2017Q2 2017C$1.28C$1.41C$2.94 billionC$3.00 billionViewN/AView Earnings Details
5/9/2017Q1 2017C$3.71C$2.79 billionViewN/AView Earnings Details
2/28/2017Q4 2016C$1.68C$3.21 billionViewN/AView Earnings Details
11/8/2016Q3 2016C$2.02C$3.23 billionViewN/AView Earnings Details
8/9/2016Q2 2016C$1.81C$3.82 billionC$3.12 billionViewN/AView Earnings Details
6/7/2016Q1 2016C$2.04C$1.74C$3.14 billionC$3.26 billionViewN/AView Earnings Details
3/15/2016Q4 2015C$3.24C$3.60 billionViewN/AView Earnings Details
10/19/2015Q3 2015C$3.50C$3.62C$3.62 billionC$3.74 billionViewN/AView Earnings Details
7/23/2015Q2 2015C$3.09C$3.17C$3.36 billionViewN/AView Earnings Details
4/29/2015Q1 2015C$2.82C$2.64 billionViewN/AView Earnings Details
2/22/2015Q4 2014C$3.30C$2.86 billionViewN/AView Earnings Details
10/20/2014Q3 2014C$2.20C$2.32 billionViewN/AView Earnings Details
7/31/2014Q2 2014C$1.98C$2.10 billionViewN/AView Earnings Details
5/8/2014C$1.83C$1.90C$2.05 billionViewN/AView Earnings Details
2/27/2014Q4 2013C$2.18C$2.39C$2.29 billionViewN/AView Earnings Details
10/31/2013Q3 2013C$1.47C$1.47C$1.71 billionC$1.61 billionViewN/AView Earnings Details
8/7/20132Q13C$0.03C$1.15 billionC$1.14 billionViewN/AView Earnings Details
5/2/2013Q1 2013C$1.28C$1.31C$1.10 billionC$1.08 billionViewN/AView Earnings Details
2/28/2013Q4 2012C$1.24C$1.23ViewN/AView Earnings Details
11/2/2012Q3 2012C$1.11C$1.11ViewN/AView Earnings Details
8/2/2012Q2 2012C$1.00C$1.02ViewN/AView Earnings Details
5/3/2012Q1 2012C$0.88C$1.12ViewN/AView Earnings Details
2/27/2012Q4 2011C$0.85C$0.90ViewN/AView Earnings Details
11/3/2011Q3 2011C$0.56C$0.63ViewN/AView Earnings Details
8/4/2011Q2 2011C$0.66ViewN/AView Earnings Details
5/9/2011Q1 2011C$0.51C$0.47ViewN/AView Earnings Details
2/24/2011Q4 2010C$0.49ViewN/AView Earnings Details
11/4/2010Q3 2010C$0.31C($0.28)ViewN/AView Earnings Details
8/5/2010Q2 2010C$0.35ViewN/AView Earnings Details
5/6/2010Q1 2010C$0.27C$0.55ViewN/AView Earnings Details
8/6/2009Q2 2009C$0.40C$0.37ViewN/AView Earnings Details
5/8/2009Q1 2009C$2.18C$0.32ViewN/AView Earnings Details
2/26/2009Q4 2008C$0.39C$0.42ViewN/AView Earnings Details
11/6/2008Q3 2008C$0.26C$0.37ViewN/AView Earnings Details
5/8/2008Q1 2008C$0.38C$0.43ViewN/AView Earnings Details
3/13/2008Q4 2007C$0.40C$0.44ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Valeant Pharmaceuticals International (TSE:VRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Valeant Pharmaceuticals International (TSE VRX) Insider Trading and Institutional Ownership History

Insider Trading History for Valeant Pharmaceuticals International (TSE:VRX)

Valeant Pharmaceuticals International (TSE VRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/15/2018Schutter Richard Urbain DeDirectorBuy15,000C$21.83C$327,450.00
3/13/2018Joseph PapaDirectorBuy30,000C$16.05C$481,500.00
3/13/2018Paul HerendeenInsiderBuy15,000C$16.10C$241,500.00
11/17/2017Schutter Richard Urbain DeDirectorBuy10,000C$14.33C$143,300.00
8/21/2017Schutter Richard Urbain DeDirectorBuy4,900C$14.35C$70,315.00
8/9/2017John PaulsonDirectorSell24,700C$14.66C$362,102.00
5/11/2017Schutter Richard Urbain DeDirectorBuy20,000C$13.90C$278,000.00
3/15/2017Schutter Richard Urbain DeDirectorBuy10,000C$10.80C$108,000.00
11/5/2015J. Michael PearsonDirectorSell350,000C$0.00C$0.00
10/21/2015Ron FarmerDirectorBuy1,000C$193.00C$193,000.00
5/26/2015Whitaker AnneInsiderBuy2,500C$234.00C$585,000.00
5/4/2015Robert Roswell Chai-OnnInsiderSell90,938C$222.54C$20,237,433.46
(Data available from 1/1/2013 forward)

Headlines

Valeant Pharmaceuticals International (TSE VRX) News Headlines

Source:
DateHeadline
Ex-Valeant Executive Guilty of Taking Pharmacy CEO’s BribeEx-Valeant Executive Guilty of Taking Pharmacy CEO’s Bribe
finance.yahoo.com - May 22 at 5:07 PM
Ex-Valeant, Philidor executives convicted of kickback schemeEx-Valeant, Philidor executives convicted of kickback scheme
finance.yahoo.com - May 22 at 5:07 PM
[$$] Former Valeant Exec Found Guilty on Charges Related to Kickback Scheme[$$] Former Valeant Exec Found Guilty on Charges Related to Kickback Scheme
finance.yahoo.com - May 22 at 5:07 PM
Insider Buying: Valeant Pharmaceuticals International Inc (VRX) Director Acquires 15,000 Shares of StockInsider Buying: Valeant Pharmaceuticals International Inc (VRX) Director Acquires 15,000 Shares of Stock
www.americanbankingnews.com - May 18 at 10:19 AM
Valeant Announces Pricing Of Private Offering Of NotesValeant Announces Pricing Of Private Offering Of Notes
finance.yahoo.com - May 17 at 6:30 PM
Ex-Valeant Executive Says He Suspected Illicit Link Was in PlaceEx-Valeant Executive Says He Suspected Illicit Link Was in Place
finance.yahoo.com - May 14 at 5:18 PM
Edited Transcript of VRX.TO earnings conference call or presentation 8-May-18 12:00pm GMTEdited Transcript of VRX.TO earnings conference call or presentation 8-May-18 12:00pm GMT
finance.yahoo.com - May 12 at 8:29 AM
FY2018 EPS Estimates for Valeant Pharmaceuticals International Inc (VRX) Lifted by AnalystFY2018 EPS Estimates for Valeant Pharmaceuticals International Inc (VRX) Lifted by Analyst
www.americanbankingnews.com - May 11 at 10:22 AM
Jefferies Group Comments on Valeant Pharmaceuticals International Incs FY2018 Earnings (VRX)Jefferies Group Comments on Valeant Pharmaceuticals International Inc's FY2018 Earnings (VRX)
www.americanbankingnews.com - May 11 at 10:19 AM
Valeant (VRX) Rallies on Earnings Beat in Q1, Raises ViewValeant (VRX) Rallies on Earnings Beat in Q1, Raises View
finance.yahoo.com - May 10 at 5:53 PM
Q3 2018 EPS Estimates for Valeant Pharmaceuticals International Inc Decreased by Analyst (VRX)Q3 2018 EPS Estimates for Valeant Pharmaceuticals International Inc Decreased by Analyst (VRX)
www.americanbankingnews.com - May 10 at 7:38 AM
Valeant Pharmaceuticals International Inc to Post Q2 2018 Earnings of $1.01 Per Share, Piper Jaffray Forecasts (VRX)Valeant Pharmaceuticals International Inc to Post Q2 2018 Earnings of $1.01 Per Share, Piper Jaffray Forecasts (VRX)
www.americanbankingnews.com - May 10 at 6:22 AM
Jim Cramer on Bausch Health: This Stock Is a BuyJim Cramer on Bausch Health: This Stock Is a Buy
finance.yahoo.com - May 9 at 5:31 PM
Valeant Earnings: One Day Later, Shares Are Still RisingValeant Earnings: One Day Later, Shares Are Still Rising
finance.yahoo.com - May 9 at 5:31 PM
Valeant Pharmaceuticals (VRX) Catches Eye: Stock Jumps 8.9%Valeant Pharmaceuticals (VRX) Catches Eye: Stock Jumps 8.9%
www.zacks.com - May 9 at 8:22 AM
Valeant Pharma (VRX) Confirms Name Change to Bausch Health (BHC)Valeant Pharma (VRX) Confirms Name Change to Bausch Health (BHC)
www.streetinsider.com - May 8 at 5:37 PM
Valeant Pharmaceuticals Turnaround Gains Momentum With a Better-Than-Expected First QuarterValeant Pharmaceuticals' Turnaround Gains Momentum With a Better-Than-Expected First Quarter
www.fool.com - May 8 at 5:37 PM
Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Still A GambleValeant Pharmaceuticals Intl Inc (VRX) Stock Is Still A Gamble
www.msn.com - May 8 at 5:37 PM
What Will Become of Valeant Pharmaceuticals?What Will Become of Valeant Pharmaceuticals?
www.msn.com - May 8 at 5:37 PM
Valeant Pharmaceuticals International (VRX) Is Up After Guidance IncreaseValeant Pharmaceuticals International (VRX) Is Up After Guidance Increase
www.nasdaq.com - May 8 at 5:37 PM
Why Valeant Pharmaceuticals International Stock Is Moving Higher TodayWhy Valeant Pharmaceuticals International Stock Is Moving Higher Today
www.msn.com - May 8 at 5:37 PM
Valeant, a new business model and now, a new nameValeant, a new business model and now, a new name
marketbeat.com - May 8 at 8:51 AM
Valeant Stock Moves Higher After FDA Approves Bowel CleanserValeant Stock Moves Higher After FDA Approves Bowel Cleanser
finance.yahoo.com - May 7 at 5:35 PM
Canadas Baby Valeant Concordia to restructure, wiping out shareholdersCanada's 'Baby Valeant' Concordia to restructure, wiping out shareholders
www.theglobeandmail.com - May 4 at 8:21 AM
Steve Sosnicks Valeant Options TradeSteve Sosnick's Valeant Options Trade
www.benzinga.com - May 4 at 8:21 AM
Ex-Valeant Official Sought Big Payday in Bribe Scam, Jury ToldEx-Valeant Official Sought 'Big Payday' in Bribe Scam, Jury Told
www.bloomberg.com - May 4 at 8:21 AM
Ex-Valeant execs lawyers urge jury to reject fraud chargeEx-Valeant exec's lawyers urge jury to reject fraud charge
finance.yahoo.com - May 3 at 5:22 PM
Ex-Valeant Official Sought ‘Big Payday’ in Bribe Scam, Jury ToldEx-Valeant Official Sought ‘Big Payday’ in Bribe Scam, Jury Told
finance.yahoo.com - May 3 at 5:22 PM
How Strategist Steve Sosnick Is Trading ValeantHow Strategist Steve Sosnick Is Trading Valeant
finance.yahoo.com - May 3 at 5:22 PM
Bausch + Lomb ULTRA® Contact Lenses Receive FDA Approval for Extended Wear IndicationBausch + Lomb ULTRA® Contact Lenses Receive FDA Approval for Extended Wear Indication
finance.yahoo.com - May 2 at 5:34 PM
Ex-Valeant Officials Trial Set to Revive Its Past PainEx-Valeant Official's Trial Set to Revive Its Past Pain
finance.yahoo.com - May 2 at 5:34 PM
[$$] Executives Fraud Trial Puts Valeant in Uncomfortable Light[$$] Executive's Fraud Trial Puts Valeant in Uncomfortable Light
finance.yahoo.com - May 1 at 5:16 PM
Valeant Pharmaceuticals International (VRX) to Release Quarterly Earnings on TuesdayValeant Pharmaceuticals International (VRX) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 8:31 AM
Bausch + Lomb Reports More Than Two Million Used Contact Lens Materials Recycled Through ONE by ONE ProgramBausch + Lomb Reports More Than Two Million Used Contact Lens Materials Recycled Through ONE by ONE Program
finance.yahoo.com - April 19 at 8:19 AM
Why Valeant Pharmaceuticals Intl Inc. Stock’s 1-Year Return of 71% Could Be Just the BeginningWhy Valeant Pharmaceuticals Intl Inc. Stock’s 1-Year Return of 71% Could Be Just the Beginning
www.fool.ca - April 16 at 5:21 PM
Valeant Pharma (VRX) to Redeem $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020Valeant Pharma (VRX) to Redeem $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020
www.streetinsider.com - April 14 at 5:08 PM
Paulson, Ackman and Sequoia: The Investors Who Took a Beating on ValeantPaulson, Ackman and Sequoia: The Investors Who Took a Beating on Valeant
finance.yahoo.com - April 13 at 5:29 PM
Valeant Pharmaceuticals International Inc’s (NYSE:VRX) Insiders Ramped Up Holdings – Should You?Valeant Pharmaceuticals International Inc’s (NYSE:VRX) Insiders Ramped Up Holdings – Should You?
finance.yahoo.com - April 13 at 5:29 PM
Arbitral Tribunal Decides In Favor Of Valeant In UCERIS ArbitrationArbitral Tribunal Decides In Favor Of Valeant In UCERIS Arbitration
finance.yahoo.com - April 12 at 5:36 PM
Valeant Announces Redemption of $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020Valeant Announces Redemption of $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020
finance.yahoo.com - April 12 at 5:36 PM
Today’s Research Reports on Valeant Pharmaceuticals, CRH Medical, Covalon Technologies and DiaMedica TherapeuticsToday’s Research Reports on Valeant Pharmaceuticals, CRH Medical, Covalon Technologies and DiaMedica Therapeutics
finance.yahoo.com - April 10 at 8:31 AM
Valeant Pharmaceuticals: Getting Better?Valeant Pharmaceuticals: Getting Better?
finance.yahoo.com - April 6 at 5:39 PM
EyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 in Anterior UveitisEyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 in Anterior Uveitis
finance.yahoo.com - April 6 at 5:39 PM
Is Valeant Pharmaceuticals Intl Inc. Still on Track?Is Valeant Pharmaceuticals Intl Inc. Still on Track?
www.fool.ca - March 31 at 5:29 PM
Can Valeant Pharmaceuticals Intl Inc. Sell its Way to Success?Can Valeant Pharmaceuticals Intl Inc. Sell its Way to Success?
www.fool.ca - March 24 at 5:12 PM
Valeant CEO compensation drops, was 138 times typical workers pay in 2017Valeant CEO compensation drops, was 138 times typical worker's pay in 2017
finance.yahoo.com - March 21 at 5:35 PM
Are Options Traders Betting on a Big Move in Valeant (VRX) Stock?Are Options Traders Betting on a Big Move in Valeant (VRX) Stock?
finance.yahoo.com - March 20 at 5:14 PM
Has Valeant Pharmaceuticals Intl Inc. Proven it Belongs in Your TFSA?Has Valeant Pharmaceuticals Intl Inc. Proven it Belongs in Your TFSA?
www.fool.ca - March 16 at 6:27 PM
Insider Buying: Valeant Pharmaceuticals Intl Inc (VRX) Insider Purchases 15,000 Shares of StockInsider Buying: Valeant Pharmaceuticals Intl Inc (VRX) Insider Purchases 15,000 Shares of Stock
www.americanbankingnews.com - March 14 at 10:41 PM
Joseph Papa Purchases 30,000 Shares of Valeant Pharmaceuticals Intl Inc (VRX) StockJoseph Papa Purchases 30,000 Shares of Valeant Pharmaceuticals Intl Inc (VRX) Stock
www.americanbankingnews.com - March 14 at 10:41 PM

SEC Filings

Valeant Pharmaceuticals International (TSE:VRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Valeant Pharmaceuticals International (TSE VRX) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.